{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Therapeutic+Proteins&page=14", "query": { "condition": "Therapeutic Proteins", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 1350, "total_pages": 135, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Therapeutic+Proteins&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Therapeutic+Proteins&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T17:30:27.526Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06385483", "title": "Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Afatinib", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2018-02-28", "completion_date": "2027-01-15", "has_results": true, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-15T17:30:27.526Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06385483" }, { "nct_id": "NCT01302886", "title": "Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Smoldering Multiple Myeloma" ], "interventions": [ { "name": "BHQ880", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2011-05", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2020-12-17", "last_synced_at": "2026-10-15T17:30:27.526Z", "location_count": 10, "location_summary": "Fayetteville, Arkansas • Tampa, Florida • Atlanta, Georgia + 7 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01302886" }, { "nct_id": "NCT05257083", "title": "A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Cilta-cel", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stichting European Myeloma Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 759, "start_date": "2023-10-10", "completion_date": "2040-08", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-10-15T17:30:27.526Z", "location_count": 27, "location_summary": "Little Rock, Arkansas • Duarte, California • San Diego, California + 21 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05257083" }, { "nct_id": "NCT03770260", "title": "Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Multiple Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Ixazomib Citrate", "type": "DRUG" }, { "name": "Pevonedistat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2020-02-10", "completion_date": "2023-07-06", "has_results": true, "last_update_posted_date": "2025-06-19", "last_synced_at": "2026-10-15T17:30:27.526Z", "location_count": 9, "location_summary": "New Haven, Connecticut • Tampa, Florida • Atlanta, Georgia + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03770260" }, { "nct_id": "NCT04647227", "title": "SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hemophilia A With Inhibitor", "Hemophilia B With Inhibitor" ], "interventions": [ { "name": "coagulation factor VIIa [recombinant]-jncw", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "American Thrombosis and Hemostasis Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "12 Years to 100 Years" }, "enrollment_count": 55, "start_date": "2021-06-28", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-01-12", "last_synced_at": "2026-10-15T17:30:27.526Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04647227" }, { "nct_id": "NCT02385786", "title": "Mindfulness-Based Cognitive Therapy Effect on Depression and C-Reactive Protein Levels After 8 Weeks of Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Mindfulness-Based Cognitive Therapy", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 43, "start_date": "2011-11", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2022-03-22", "last_synced_at": "2026-10-15T17:30:27.526Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02385786" }, { "nct_id": "NCT00066599", "title": "Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Neuroblastoma", "Neutropenia", "Sarcoma" ], "interventions": [ { "name": "voriconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "2 Years to 11 Years" }, "enrollment_count": null, "start_date": "2003-06", "completion_date": "2004-06", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-10-15T17:30:27.526Z", "location_count": 7, "location_summary": "Orange, California • San Diego, California • Bethesda, Maryland + 4 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00066599" }, { "nct_id": "NCT03272633", "title": "Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia in Remission", "Hematopoietic Cell Transplantation Recipient", "JAK2 Gene Mutation", "Loss of Chromosome 17p", "Mantle Cell Lymphoma", "Minimal Residual Disease", "Myelodysplastic Syndrome", "Non-Hodgkin Lymphoma", "Plasma Cell Myeloma", "RAS Family Gene Mutation", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Hematologic Malignancy", "Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Therapy-Related Acute Myeloid Leukemia", "Therapy-Related Myelodysplastic Syndrome", "TP53 Gene Mutation" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Irradiated Allogeneic Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2020-10-26", "completion_date": "2022-09-22", "has_results": true, "last_update_posted_date": "2023-06-26", "last_synced_at": "2026-10-15T17:30:27.526Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03272633" }, { "nct_id": "NCT06983158", "title": "A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Developmental and Epileptic Encephalopathy" ], "interventions": [ { "name": "gene therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Capsida Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Months", "maximum_age": "7 Years", "sex": "ALL", "summary": "18 Months to 7 Years" }, "enrollment_count": 1, "start_date": "2025-07-03", "completion_date": "2026-05-26", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-10-15T17:30:27.526Z", "location_count": 4, "location_summary": "Aurora, Colorado • New York, New York • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06983158" }, { "nct_id": "NCT05142722", "title": "Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dyslipidemias", "High Cholesterol", "Hypercholesterolemia", "Familial Hypercholesterolemia", "Atherosclerotic Cardiovascular Disease" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Obicetrapib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NewAmsterdam Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2530, "start_date": "2021-12-15", "completion_date": "2024-09-26", "has_results": true, "last_update_posted_date": "2025-09-19", "last_synced_at": "2026-10-15T17:30:27.526Z", "location_count": 69, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Saraland, Alabama + 60 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Saraland", "state": "Alabama" }, { "city": "Sheffield", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT05142722" } ] }